var data={"title":"Eletriptan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Eletriptan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6096?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=eletriptan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Eletriptan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164501\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Relpax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855134\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Relpax&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164525\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimigraine Agent;</li>\n      <li>\n        Serotonin 5-HT<sub>1B, 1D</sub> Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164504\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If the first dose is ineffective, diagnosis needs to be re-evaluated. Safety of treating &gt;3 headaches/month has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute migraine:</b> Oral: Initial: 20 to 40 mg as a single dose (maximum: 40 mg/dose); if the headache improves but returns, dose may be repeated after 2 hours have elapsed since first dose (maximum: 80 mg/day). <b>Note:</b> 80 mg single doses have been evaluated in clinical trials, however this dose has been associated with a slightly greater incidence of adverse reactions (McCormack 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062899\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164505\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, adjustment likely not needed based on pharmacokinetic analysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164506\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164482\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relpax: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relpax: 40 mg [contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164470\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22757697\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Administer orally as soon as symptoms appear. May take with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164483\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Migraines:</b> Acute treatment of migraine, with or without aura in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164475\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain (2% to 4%; chest tightness, pain, and pressure), palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (6% to 7%), drowsiness (6% to 7%), headache (4%), paresthesia (3% to 4%), chills, hypertonia, hypoesthesia, pain, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (8%), xerostomia (3% to 4%), abdominal pain (2%; pain, discomfort, stomach pain, cramps, and pressure), dyspepsia (2%), dysphagia (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (4% to 10%), back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Abnormal dreams, abnormal hepatic function tests, agitation, alopecia, amnesia, anaphylactoid reaction, anaphylaxis, anemia, angina pectoris, angioedema, aphasia, ataxia, cardiac arrhythmia, confusion, constipation, depersonalization, depression, diarrhea, diplopia, dysgeusia, dyspnea, dystonia, edema, emotional lability, esophagitis, euphoria, gingivitis, hallucination, hyperesthesia, hyperglycemia, hyperkinesia, hypersensitivity reaction, hypertension, impotence, increased creatine phosphokinase, insomnia, ischemic colitis, lacrimation, manic behavior, myalgia, myasthenia, myocardial infarction, nervousness, paralysis, peripheral edema, peripheral vascular disorder, photophobia, polyuria, Prinzmetal angina, pruritus, purpura, seizure, sensation of pressure (chest/neck/throat/jaw), shock, sialorrhea, skin discoloration, skin rash, speech disturbance, stupor, syncope, tachycardia, thrombophlebitis, tinnitus, tongue edema, tremor, twitching, urinary frequency, urticaria, vasospasm, ventricular fibrillation, visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164486\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ischemic coronary artery disease (eg, angina pectoris, history of myocardial infarction, documented silent ischemia); coronary artery vasospasm, including Prinzmetal angina; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; history of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; recent use (within 24 hours) of treatment with another 5-HT<sub>1</sub> agonist, or an ergotamine-containing or ergot-type medication (eg, dihydroergotamine or methysergide); recent use (within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir; known hypersensitivity to eletriptan or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Cardiac arrhythmias (especially tachycardias), valvular heart disease, congenital heart disease, atherosclerotic disease; ophthalmoplegic migraine; Raynaud syndrome; severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for serotonin 5-HT<sub>1</sub> receptor agonists (triptans) in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164473\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/Anaphylactoid reactions: Anaphylaxis, anaphylactoid, and hypersensitivity reactions (including angioedema) have occurred; may be life-threatening or fatal. Use is contraindicated in patients with known hypersensitivity to eletriptan.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT<sub>1</sub> agonist administration; some events have occurred within a few hours of administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG. Use is contraindicated in patients with ischemic or vasospastic CAD and Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke (some fatal) have been reported with 5-HT<sub>1</sub> agonist administration. Use is contraindicated in patients with a history of stroke or transient ischemic attack.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has also been reported on rare occasions in patients with and without a history of hypertension. Monitor blood pressure; use is contraindicated in patients with uncontrolled hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may rarely occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce eletriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended. If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases. Discontinue eletriptan if serotonin syndrome is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasospasm-related events: Peripheral vascular ischemia, gastrointestinal vascular ischemia/infarction, and Raynaud syndrome have been reported with 5-HT<sub>1</sub> agonists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Not recommended for use in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Only indicated for treatment of acute migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic or basilar migraine. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine. Acute migraine agents (eg, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Blood pressure was increased to a greater extent in elderly subjects than in younger subjects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164519\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164477\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8517&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Monoamine Oxidase Inhibitor): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if selegiline, rasagiline, or safinamide is combined with a serotonin modulator. Use of transdermal selegiline with serotonin modulators is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Eletriptan. Management: The use of eletriptan within 72 hours of a moderate CYP3A4 inhibitor should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Eletriptan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.<b> Exceptions: </b>Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUMAtriptan: Serotonin 5-HT1D Receptor Agonists may enhance the adverse/toxic effect of SUMAtriptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164499\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">A high-fat meal increases bioavailability. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164479\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164488\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Information related to eletriptan use in pregnancy is limited (K&auml;ll&eacute;n 2011; Nezvalov&aacute;-Henriksen, 2010; Nezvalov&aacute;-Henriksen 2012). Until additional information is available, other agents are preferred for the initial treatment of migraine in pregnancy (Da Silva 2012; MacGregor 2012; Williams 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11310537\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Eletriptan is present in breast milk. Eight women were given a single dose of eletriptan 80 mg. The amount of drug detected in breast milk over 24 hours was ~0.02% of the maternal dose and the milk-to-plasma ratio was variable. The presence of the active metabolite was not measured. The manufacturer recommends that caution be exercised when administering eletriptan to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22757699\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Headache severity; signs/symptoms suggestive of angina; blood pressure, heart rate, and/or ECG with first dose in patients with likelihood of unrecognized coronary disease, such as patients with significant hypertension, hypercholesterolemia, obese patients, patients with diabetes, smokers with other risk factors or strong family history of coronary artery disease; signs/symptoms of serotonin syndrome and hypersensitivity reactions </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164472\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective agonist for serotonin (5-HT<sub>1B</sub>,  5-HT<sub>1D</sub>, and 5-HT<sub>1F</sub>  receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164485\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 138 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~85%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4; forms one metabolite (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~50%, increased with high-fat meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~4 hours (Elderly: 4.4 to 5.7 hours); Metabolite: ~13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1.5 to 2 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164487\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Eletriptan Hydrobromide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (6): $368.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (6): $368.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Relpax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $74.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (6): $448.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164489\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elle (PK);</li>\n      <li>Relert (BE, CR, DO, FI, GT, IL, LU, NI, PA, PT, SV);</li>\n      <li>Relpax (AE, AT, AU, BB, BG, BH, BR, CH, CL, CO, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HN, IE, IS, IT, JO, KW, LV, MX, NL, NO, NZ, PL, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo; <i>N Engl J Med</i>, 2005, 352:1112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/15784664/pubmed\" target=\"_blank\" id=\"15784664\">15784664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Da Silva AN and Tepper SJ, &quot;Acute Treatment of Migraines,&quot; <i>CNS Drugs</i>, 2012, 26(10):823-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/22823482/pubmed\" target=\"_blank\" id=\"22823482\">22823482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in sweden. <i>Drug Saf. </i>2011;34(8):691-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/21751829/pubmed\" target=\"_blank\" id=\"21751829\">21751829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor EA, &quot;Headache in Pregnancy,&quot; <i>Neurol Clin</i>, 2012, 30(3):835-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/22840792/pubmed\" target=\"_blank\" id=\"22840792\">22840792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCormack PL, Keating GM. Eletriptan: a review of its use in the acute treatment of migraine. <i>Drugs.</i> 2006;66(8):1129-1149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/16789799/pubmed\" target=\"_blank\" id=\"16789799\">16789799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nezvalov&aacute;-Henriksen K, Spigset O, and Nordeng HM, &quot;Errata in 'Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study,'&quot; <i>Headache</i>, 2012, 52(8):1319-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/22946832/pubmed\" target=\"_blank\" id=\"22946832\">22946832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nezvalov&aacute;-Henriksen K, Spigset O, and Nordeng H, &quot;Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study,&quot; <i>Headache</i>, 2010, 50(4):563-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/20132339/pubmed\" target=\"_blank\" id=\"20132339\">20132339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Relpax (eletriptan) [prescribing information]. New York, NY: Pfizer; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Relpax (eletriptan) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams SH and Kehr HA, &quot;An Update in the Treatment of Neurologic Disorders During Pregnancy-Focus on Migraines and Seizures,&quot; <i>J Pharm Pract</i>, 2012, 25(3):341-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eletriptan-drug-information/abstract-text/22550159/pubmed\" target=\"_blank\" id=\"22550159\">22550159</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8517 Version 154.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F164501\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855134\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F164525\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F164504\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062899\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F164505\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F164506\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164482\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F164470\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22757697\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F164483\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164475\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164486\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F164473\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F164519\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F164477\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F164499\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F164479\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F164488\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11310537\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22757699\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F164472\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F164485\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F164487\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F164489\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8517|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=eletriptan-patient-drug-information\" class=\"drug drug_patient\">Eletriptan: Patient drug information</a></li></ul></div></div>","javascript":null}